Year: 2025
Type: article
Study design: Clinical Trial
Abstract: Background Bempedoic acid (BA) is a novel oral cholesterol-lowering drug. So far, in vivo evidence on potential drug–drug interactions via the cytochrome P450 (CYP) enzymes is lacking. Methods In a clinical trial, we evaluated the effect of BA on microdosed probe drugs using a limited sampling strategy in healthy volunteers. The outcome measures were as follows: 1) the omeprazole AUC0–4h and hydroxylation index (HI) after a 100 µg dose to evaluate CYP2C19 activity, 2) the midazolam AUC2–4h after a 30 µg dose to evaluate CYP3A activity, and 3) the yohimbine AUC0–4h after a 50 µg dose to evaluate CYP2D6 activity. Partial areas under the curve (AUCs) were evaluated at baseline and under BA steady state. The endpoints were the geometric mean ratios (GMRs) with 95% confidence intervals (CI) of the partial AUCs. Results In 15 participants, the AUC0–4h of omeprazole and its HI significantly decreased (GMR: 0.75, 90% CI: 0.66–0.85; change in HI p < 0.0001). There was no change in the AUC2–4h of midazolam (GMR: 1.18, 90% CI: 0.87–1.61) and AUC0–4h of yohimbine (GMR: 0.92, 90% CI: 0.75–1.14). Conclusion In healthy volunteers, BA was a mild inducer of CYP2C19 and did not affect CYP3A or CYP2D6 activity.
Source: Frontiers in Pharmacology
Authors: Felicitas Stoll, Salvatore Amato, Jürgen Burhenne, Antje Blank
Institutions: Heidelberg University, University Hospital Heidelberg
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W4409240416